Coronary Artery Heart Disease
Conditions
Interventions
1:change clopidogrel with ticagrelor
Sponsors
Cardiovascular Department, Peking University Third Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Patients must meet the following criteria: 1. Men or women aged 18~75 years; 2. A clinical diagnosis of acute coronary syndrome; 3. Undergone elective percutaneous coronary intervention; 4. Carrying CYP2C19 loss-of-function polymorphisms (*2 and/or *3); 5. Written informed consen.
Exclusion criteria
Exclusion criteria: Patients will be excluded from participation in this study for any of the following reasons: 1. Patients of acute ST-segment elevation myocardial infarction or high risk non ST-segment elevation myocardial infarction who have undergone primary or urgent PCI; 2. Ticagrelor has been taken; 3. Taking 150mg clopidogrel per day; 4. Contraindications of Ticagrelor (e.g. drug allery, moderate to severe liver disease, platelet count less than 100*10^9 per litre, active bleeding or history of bleeding, history of intracranial hemorrhage, major operation has been performed in last 30 days and potent CYP3A4 inhibitors has been taken); 5. Thrombolytic agents or platelet glycoprotein IIb/IIIa receptor antagonists had been taken during perioperative period of PCI; 6. With the necessity to continue taking oral-anticoagulant agents; 7. Bradycardia; 8. Weight less than 60kg; 9. End-stage chronic congestive heart failure or LVEF is less than 30% measured with echocardiography; 10. Severe lung, liver, or renal diseases; 11. Having or being suspected to have been pregnant or nursing; 12. Participed in any investigational drug study in past 30 days.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Inhibitory Rate of Blood Platelet Aggregation;P2Y12 Reaction Units; | — |
Countries
China
Contacts
Public ContactWei Zhao
Outcome results
None listed